Proliferative Diabetic Retinopathy Market to surge owing to Rising Adoption of Diabetes Management Devices

 

Market Overview
Proliferative diabetic retinopathy (PDR) is a vision-threatening retinal complication of diabetes, where abnormal new blood vessels grow on the surface of the retina or in the clear, vitreous gel that fills the middle of the eye. The overall prevalence of diabetic retinopathy is estimated to be 35.4% amongst diabetics. Proliferative retinopathy develops due to long-term exposure of retinal tissues to high blood sugar levels, which results in damage to blood vessels in the retina. The key symptoms include blurred or diminished vision, dark or empty spots in the field of vision. In severe cases, it can even lead to vision loss. Retinal specialists usually diagnose and monitor PDR with eye exams and retinal photography or imaging tests. Laser photocoagulation treatment helps reduce the production of abnormal blood vessels.

The Global Proliferative Diabetic Retinopathy Market is estimated to be valued at US$ 863 million in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period 2024-2030.

Key Takeaways
Key players operating in the Proliferative Diabetic Retinopathy are Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Bausch Health Companies Inc.

The rising prevalence of diabetes across the globe is a major factor driving the growth of the proliferative diabetic retinopathy market. As per the International Diabetes Federation, the number of diabetic adults worldwide has risen from 463 million in 2019 to 537 million in 2021. Early detection and diagnosis are crucial in preventing vision loss from proliferative retinopathy. There has been an increased adoption of diabetes management devices like blood glucose monitors that make it convenient to track glucose levels regularly and prevent complications.

Technological advancements are also supporting the management of PDR. Novel drug delivery methods like intravitreal injections enable targeted delivery of anti-VEGF drugs directly to the back of the eye. Advances in retinal imaging devices provide sharper visualization of the retina to facilitate precise diagnosis and treatment. Tele-ophthalmology is emerging as an effective screening method using digital retinal images.

Market Trends
The key trends in the proliferative diabetic retinopathy market include the rising demand for advanced laser photocoagulation systems and the increasing preference for combination therapy. New laser systems offer wider scan areas, higher precision and atraumatic pulses for faster, more effective treatment of neovascularization. Combination therapy using anti-VEGF drugs along with laser treatment is gaining traction as it provides synergistic clinical outcomes.

Market Opportunities
The untapped rural markets in developing regions present significant opportunities for market players. Partnerships with eye hospitals and diabetes clinics can aid efficient screening of at-risk populations. Contract manufacturing partnerships allow the establishment of local manufacturing facilities to reduce production and distribution costs. Development of biosimilars and novel drug formulations like sustained-release intravitreal implants also offer lucrative growth opportunities.

Impact of COVID-19 on Proliferative Diabetic Retinopathy Market Growth

The COVID-19 pandemic posed significant challenges for the proliferative diabetic retinopathy market. During the initial lockdown phases in early 2020, major healthcare resources were diverted to address the rapidly rising cases of COVID-19. Non-emergency medical procedures and routine eye checkups were postponed or suspended. This led to a decrease in new cases being diagnosed and treated for proliferative DR during this period. There was a major disruption in the regular screening and treatment process for thisretinal disease.

With lockdowns being gradually lifted in late 2020, healthcare systems have tried to restore retina services and eye care. However, patient visits are still lower than the pre-pandemic levels due to various factors like fear of virus exposure and priority being given to COVID-19 care. Teleophthalmology has helped to some extent in remote patient monitoring and management of stable cases. However, more complex proliferative DR requiring laser therapy or intraocular injections could not be addressed adequately through telehealth. The market has been recovering steadily through 2021 but challenges of managing diabetes and preventing progression of the disease remain.

Going forward, efforts must be made to raise awareness about continued eye care amid the pandemic. Prioritizing screening and treatment for advanced cases will be critical. Adopting stringent safety and sanitization protocols can help generate patient confidence in seeking eye care. Telemedicine may serve as an important complement to in-person services. Addressing the social determinants influencing diabetes and eye health is also a long-term strategy.

In terms of geographical distribution, North America accounts for the largest share of the proliferative diabetic retinopathy market currently in terms of value. This is attributed to factors like high diabetes prevalence, strong healthcare infrastructure and widespread medical coverage in the region facilitating early diagnosis and management. Asia Pacific is projected as the fastest growing regional market given the rising burden of diabetes in many developing nations and increasing access to retinal care. Countries like China, India and Japan will be major domestic markets and also medical tourism destinations for retina procedures.

The Proliferative Diabetic Retinopathy Market in terms of value is primarily concentrated in North America currently owing to high diabetes rates and well-established healthcare systems facilitating early diagnosis and management. However, the Asia Pacific region is poised to be the fastest growing market for Proliferative Diabetic Retinopathy given the rising burden of diabetes in developing countries of the region and improving access to retinal care services in nations such as China, India and Japan.

Get more insights on this topic : https://nouw.com/ajay100/diabetic-retinopathy-market-to-witness-high-growth-due-to-increase-prevalence-of-diabetic-38619798

What Are The Key Data Covered In This Proliferative Diabetic Retinopathy  Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Proliferative Diabetic Retinopathy 's growth between 2024 and 2031.

:- Accurate calculation of the size of the Proliferative Diabetic Retinopathy  and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Proliferative Diabetic Retinopathy  Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Proliferative Diabetic Retinopathy  vendors

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it